Assessment of Y-90 Radioembolization Treatment Response for Hepatocellular Carcinoma Cases Using MRI Radiomics.

IF 0.9 Q4 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING Molecular Imaging and Radionuclide Therapy Pub Date : 2024-10-07 DOI:10.4274/mirt.galenos.2024.59365

Mennaallah Mahmoud, Ko-Han Lin, Rheun-Chuan Lee, Chien-An Liu

{"title":"Assessment of Y-90 Radioembolization Treatment Response for Hepatocellular Carcinoma Cases Using MRI Radiomics.","authors":"Mennaallah Mahmoud, Ko-Han Lin, Rheun-Chuan Lee, Chien-An Liu","doi":"10.4274/mirt.galenos.2024.59365","DOIUrl":null,"url":null,"abstract":"Objectives: This study aimed to investigate the ability of radiomics features extracted from magnetic resonance imaging (MRI) images to differentiate between responders and non-responders for hepatocellular carcinoma (HCC) cases who received Y-90 transarterial radioembolization treatment.Methods: Thirty-six cases of HCC who underwent MRI scans after Y-90 radioembolization were included in this study. Tumors were segmented from MRI T2 images, and then 87 radiomic features were extracted through the LIFEx package software. Treatment response was determined 9 months after treatment through the modified response evaluation criteria in solid tumours (mRECIST).Results: According to mRECIST, 28 cases were responders and 8 cases were non-responders. Two radiomics features, \"Grey Level Size Zone Matrix (GLSZM)-Small Zone Emphasis\" and \"GLSZM-Normalized Zone Size Non-Uniformity\", were the radiomics features that could predict treatment response with the area under curve (AUC)= 0.71, sensitivity= 0.93, and specificity= 0.62 for both features. Whereas the other 4 features (kurtosis, intensity histogram root mean square, neighbourhood gray-tone difference matrix strength, and GLSZM normalized grey level non-uniformity) have a relatively lower but acceptable discrimination ability range from AUC= 0.6 to 0.66.Conclusion: MRI radiomics analysis could be used to assess the treatment response for HCC cases treated with Y-90 radioembolization.","PeriodicalId":44681,"journal":{"name":"Molecular Imaging and Radionuclide Therapy","volume":"33 3","pages":"156-166"},"PeriodicalIF":0.9000,"publicationDate":"2024-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Molecular Imaging and Radionuclide Therapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4274/mirt.galenos.2024.59365","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}

引用次数: 0

Abstract

Objectives: This study aimed to investigate the ability of radiomics features extracted from magnetic resonance imaging (MRI) images to differentiate between responders and non-responders for hepatocellular carcinoma (HCC) cases who received Y-90 transarterial radioembolization treatment.

Methods: Thirty-six cases of HCC who underwent MRI scans after Y-90 radioembolization were included in this study. Tumors were segmented from MRI T2 images, and then 87 radiomic features were extracted through the LIFEx package software. Treatment response was determined 9 months after treatment through the modified response evaluation criteria in solid tumours (mRECIST).

Results: According to mRECIST, 28 cases were responders and 8 cases were non-responders. Two radiomics features, "Grey Level Size Zone Matrix (GLSZM)-Small Zone Emphasis" and "GLSZM-Normalized Zone Size Non-Uniformity", were the radiomics features that could predict treatment response with the area under curve (AUC)= 0.71, sensitivity= 0.93, and specificity= 0.62 for both features. Whereas the other 4 features (kurtosis, intensity histogram root mean square, neighbourhood gray-tone difference matrix strength, and GLSZM normalized grey level non-uniformity) have a relatively lower but acceptable discrimination ability range from AUC= 0.6 to 0.66.

Conclusion: MRI radiomics analysis could be used to assess the treatment response for HCC cases treated with Y-90 radioembolization.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

利用磁共振成像放射组学评估肝细胞癌病例的 Y-90 放射栓塞治疗反应

研究目的本研究旨在探讨从磁共振成像（MRI）图像中提取的放射组学特征区分接受 Y-90 经动脉放射栓塞治疗的肝细胞癌（HCC）病例中应答者和非应答者的能力：本研究纳入了 36 例接受 Y-90 经动脉放射栓塞治疗后接受磁共振成像扫描的 HCC 患者。从 MRI T2 图像中分割肿瘤，然后通过 LIFEx 软件包提取 87 个放射学特征。治疗9个月后，通过实体瘤改良反应评估标准（mRECIST）确定治疗反应：结果：根据 mRECIST，28 例有反应，8 例无反应。灰度大小区矩阵（GLSZM）-小区强调 "和 "GLSZM-归一化区大小不均匀 "这两个放射组学特征可以预测治疗反应，其曲线下面积（AUC）= 0.71，灵敏度= 0.93，特异度= 0.62。而其他 4 个特征（峰度、强度直方图均方根、邻近灰阶差矩阵强度和 GLSZM 归一化灰阶不均匀度）的辨别能力相对较低，但在 AUC= 0.6 至 0.66 之间，是可以接受的：磁共振成像放射组学分析可用于评估接受Y-90放射性栓塞治疗的HCC病例的治疗反应。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Molecular Imaging and Radionuclide Therapy RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING-

CiteScore

1.30

自引率

0.00%

发文量

期刊介绍： Molecular Imaging and Radionuclide Therapy (Mol Imaging Radionucl Ther, MIRT) is publishes original research articles, invited reviews, editorials, short communications, letters, consensus statements, guidelines and case reports with a literature review on the topic, in the field of molecular imaging, multimodality imaging, nuclear medicine, radionuclide therapy, radiopharmacy, medical physics, dosimetry and radiobiology.